Japanese BAY80-6946 Monotherapy Phase I Study

Inclusion Criteria:

* Cancer patients
* Japanese patients, who are at least 20 years of age
* Histological or cytological documentation of non-hematologic, malignant solid tumours, excluding primary brain or spinal tumours, with no past or current involvement in the central nervous system (CNS)
* At least one measurable lesion or evaluable disease according to RECIST (version 1.1)
* Eastern Cooperative Oncology performance status (ECOG-PS) of 0 or 1
* Life expectancy of at least 12 weeks
* Advanced or refractory solid tumours not amenable to standard therapy, at the first screening examination/visit

Exclusion Criteria:

* Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of first study treatment. Patients must have recovered from the toxic effects of the previous anti-cancer chemotherapy or immunotherapy by the investigator (with the exception of alopecia).
* Radiotherapy to target lesions during study or within 4 weeks of first study treatment
* Investigational drug therapy outside of this trial during or within 4 weeks of first study treatment
* Current diagnosis of Type I or II diabetes mellitus or fasting blood glucose level \>125 mg/dL at screening, and/or HbA1c\>/= 6.5%
* Past and current histories of cardiac disease congestive heart failure \> New York Heart Association (NYHA) Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset of angina within 3 months prior to study entry or unstable angina or ventricular cardiac arrhythmias requiring anti-arrhythmic therapy
* Active and clinically serious infections \>Grade 2 (National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] version 4.03)
* Uncontrolled hypertension defined as systolic blood pressure \>150 mm Hg or diastolic pressure \> 90 mm Hg, despite optimal medical management
* Patients undergoing renal dialysis
* Pregnant or breast feeding women